Conference Agenda

Session
Poster - 02 Drug design: Drug design
Time:
Sunday, 15/Aug/2021:
5:10pm - 6:10pm

Session Chair: Begoña Heras
Session Chair: Anton V. Zavialov

 


Presentations

Poster session abstracts

Radomír Kužel



Fragment Based Drug Discovery of SARS-CoV-2 Main Protease

Weixiao Song, Sen Li, AhWing Edith Chan, Alun Coker

University College London, London, United Kingdom



Repurposing an ancient protein core structure: structural studies on FmtA, a novel esterase of Staphylococcus aureus

vikram Dalal1, Pramod Kumar1, Gaddy Rakhaminov2, Aneela Qamar2, Xin Fan2, Howard Hunter2, Shailly Tomar1, Dasantila Golemi-Kotra2, Pravindra Kumar1

1Department of Biotechnology, IIT Roorkee, Roorkee, India; 2Department of Biology,York University, 4700 Keele Street, Toronto, Canada



Studies of LysSi3, a Gram-negative targeting endolysin with broad bactericidal activity.

Tatyana Prudnikova1, Daria V Vasina2, Dmitry Loginov1, Ivana Kuta Smatanova1

1Laboratory of Structural Chemistry, Institute of Chemistry, Faculty of Science, University of South Bohemia in České Budějovice, Czech Republic; 2N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.



Structural insight into the degradation selectivity of C2H2 zinc finger by thalidomide metabolite

Hirotake Furihata1, Satoshi Yamanaka2, Toshiaki Honda3, Norio Shibata3, Masaru Tanokura1, Tatsuya Sawasaki2, Takuya Miyakawa1

1Graduate School of Agricultural and Life Sciences, The University of Tokyo; 2Proteo-Science Center, Ehime University; 3Life Science and Applied Chemistry, Graduate School of Engineering, Nagoya Institute of Technology



Structure determination of the motor domain of centromere associated protein E

Asuka Shibuya1, Naohisa Ogo2, Jun-ichi Sawada2, Akira Asai2, Hideshi Yokoyama1

1Faculty of Pharmaceutical Sciences, Tokyo University of Science; 2Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka



Structural studies towards the development of an oral main protease (Mpro) inhibitor to treat SARS-CoV-2 infection

Joanne Lemieux1, Muhammad Bashir Khan1, Arutyunova Arutyunova1, Jimmy Lu1, James Nieman3, D. Lorne Tyrrell2, Howard S Young1

1Department of Biochemistry, University of Alberta, Edmonton, Canada; 2Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada; 3Li Ka Shing Applied Virology Institute, University of Alberta, Edmonton, Alberta, Canada,